Drug Type Synthetic peptide |
Synonyms 5-oxo-L-prolyl-L-histidyl-L-prolinamide, L-pyroglutamyl-L-histidyl-L-prolineamide, Protirelin (JP17/USAN/INN) + [15] |
Target |
Mechanism TRHR agonists(Thyrotropin releasing hormone receptor agonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhaseApproved |
First Approval Date US (05 Nov 1976), |
RegulationOrphan Drug (US) |
Molecular FormulaC16H22N6O4 |
InChIKeyXNSAINXGIQZQOO-SRVKXCTJSA-N |
CAS Registry24305-27-9 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D00176 | Protirelin |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Consciousness Disorders | JP | Teva Takeda Pharma Ltd.Startup | 01 Oct 1985 |
Subarachnoid Hemorrhage | JP | Teva Takeda Pharma Ltd.Startup | 01 Oct 1985 |
Hypothyroidism | US | 05 Nov 1976 |
Phase 2 | 96 | aeyhjlsqvv(gooanokaza) = nmzamsquvr xjwvawlwsf (nyipvqygxm, vlyfznwyqp - yuhpbptiqp) View more | - | 08 Aug 2018 | |||
Phase 2 | 11 | Placebo | bmhjsvxcos(iocqfvolzt) = pulretkhtp vvvwbifruu (xefwumljpv, xnvwjsgmaf - xmibgnjfbb) View more | - | 03 May 2011 |